HLA-A and neoplasm: The same immunization scheme efficiently generated CD8+ T cell responses specific for different tumor-associated HLA-A*02 epitopes including Survivin95–104, Mammaglobin83–92, HER3356–364, and cMET654–662 (Figure 3E) [33,34,35].